Literature DB >> 9629879

Aetiology and prevention of emesis induced by radiotherapy.

P C Feyer1, A L Stewart, O J Titlbach.   

Abstract

The introduction of new antiemetics has resulted in renewed interest in the aetiology and control of radiation induced emesis. Studies both with fractionated treatment and with high-dose single exposures have clearly demonstrated the value of the 5HT3 receptor antagonist antiemetics. This paper reviews the selection of optimal antiemetics.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9629879     DOI： 10.1007/s005200050163

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  14 in total

Review 1.  Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.

Authors:  Petra Feyer; M Heinrich Seegenschmiedt; Maria Steingraeber
Journal:  Support Care Cancer       Date:  2005-07-26       Impact factor: 3.603

2.  Biological Effects of Space Radiation and Development of Effective Countermeasures.

Authors:  Ann R Kennedy
Journal:  Life Sci Space Res (Amst)       Date:  2014-04-01

3.  Impact of radiation-induced nausea and vomiting on quality of life.

Authors:  Caitlin Yee; Leah Drost; Liying Zhang; Bo Angela Wan; Vithusha Ganesh; May Tsao; Elizabeth Barnes; Mark Pasetka; Carlo DeAngelis; Edward Chow
Journal:  Support Care Cancer       Date:  2018-05-28       Impact factor: 3.603

4.  Effects of solar particle event proton radiation on parameters related to ferret emesis.

Authors:  J K Sanzari; X S Wan; G S Krigsfeld; G L King; A Miller; R Mick; D S Gridley; A J Wroe; S Rightnar; D Dolney; A R Kennedy
Journal:  Radiat Res       Date:  2013-07-24       Impact factor: 2.841

5.  Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).

Authors:  Steven Ades; M Halyard; K Wilson; T Ashikaga; R Heimann; S Kumar; W Blackstock
Journal:  Support Care Cancer       Date:  2016-12-28       Impact factor: 3.603

6.  Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009.

Authors:  Petra Christine Feyer; Ernesto Maranzano; Alexander Molassiotis; Fausto Roila; Rebecca A Clark-Snow; Karin Jordan
Journal:  Support Care Cancer       Date:  2010-08-10       Impact factor: 3.603

7.  Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study.

Authors:  K Dennis; C De Angelis; F Jon; N Lauzon; M Pasetka; L Holden; E Barnes; C Danjoux; A Sahgal; M Tsao; E Chow
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

8.  One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.

Authors:  Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

9.  Aprepitant reduces chemotherapy-induced vomiting in children and young adults with brain tumors.

Authors:  Kelly Duggin; Kelly Tickle; Gina Norman; Jie Yang; Chong Wang; Shane J Cross; Amar Gajjar; Belinda Mandrell
Journal:  J Pediatr Oncol Nurs       Date:  2014-06-27       Impact factor: 1.636

10.  The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting.

Authors:  Hamid Emami; Simin Hematti; Seyed Masoud Saeidian; Awat Feizi; Shahin Taheri; Pourya Adeli; Golshan Mahmoudi
Journal:  J Res Med Sci       Date:  2015-04       Impact factor: 1.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.